HRH2 and myeloid sarcoma: H2R antagonists also act on other cell types, including endothelial cells at the blood-brain barrier (BBB), mast cells and cells of the immune system (for example, T-lymphocytes, monocytes and dendritic cells (DCs)), that play central roles in orchestrating immune-mediated pathology in MS.